局部区域治疗后肝脏硬度变化不能预测肝癌结局:弹性成像作为预后工具的局限性
本前瞻性研究纳入100例接受局部区域治疗(消融、TACE、TARE)的肝癌患者,最终76例完成分析。2D-SWE显示消融后(p=0.02)和TACE后(p=0.04)肿瘤硬度增加,TARE后稳定(p=0.69);但基线肿瘤硬度、瘤周硬度及肝硬度均与短期临床结局无显著相关(p=0.72、0.61、0.29)。作者认为2D-SWE可监测组织变化,但尚无证据支持其预测治疗反应或临床结局,需在更大同质队列中验证。
要点
- 消融后(p=0.02)和TACE后(p=0.04)肿瘤硬度增加,TARE后稳定(p=0.69)。
- 瘤周及肝实质硬度治疗后未见显著变化。
- 基线肿瘤、瘤周及肝硬度均与6个月内临床结局无显著相关(p=0.72、0.61、0.29)。
核心结论
- 2D-SWE可测得局部区域治疗后肿瘤硬度的变化,提示其可能用于监测组织改变。
- 但未发现证据支持2D-SWE能预测治疗反应或临床结局。
研究设计与样本
- 前瞻性研究,纳入100例适合局部区域治疗的肝癌患者,最终76例完成分析(排除弹性成像采集技术限制、无法接受治疗或失访者)。
- 治疗前及治疗后1个月以2D-SWE测量肿瘤组织、瘤周区域及邻近肝组织硬度。
- 收集临床与影像学资料,包括截至6个月的肿瘤反应;按治疗类型行亚组分析,但样本量有限,结果应谨慎解释并视为探索性。
关键影像表现/征象
- 消融后肿瘤硬度增加(p=0.02),TACE后肿瘤硬度增加(p=0.04),TARE后肿瘤硬度保持稳定(p=0.69)。
- 治疗后瘤周硬度与肝硬度均未检测到显著变化。
诊断标准与关键数值
- 基线肿瘤硬度与肿瘤类型(p=0.48)及病灶大小(p=0.35)均无相关性。
- 基线肿瘤硬度(p=0.72)、瘤周硬度(p=0.61)及肝硬度(p=0.29)与短期临床结局均无显著相关。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 100例中最终仅76例纳入分析,部分因弹性成像采集技术限制、无法接受治疗或失访被排除。
- 亚组分析因样本量有限,结果应谨慎解释并视为探索性。
- 作者指出这些发现应视为初步结果,需在更大且同质的队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This prospective study evaluates the exploratory value of tumor and liver stiffness, measured pre-operatively by 2D shear wave elastography (2D-SWE), in patients with liver cancer undergoing locoregional therapies, including ablation, transarterial chemoembolization (TACE), and transarterial radioembolization (TARE). The aim is to assess whether stiffness changes occur after treatment and to explore their possible association with clinical outcomes.
METHODS: 100 patients with liver cancer eligible for locoregional treatment were enrolled. Tumoral tissue, peritumoral area, and proximal liver tissue stiffness were evaluated by 2D-SWE before treatment and one month afterward. Clinical and radiological data were collected, including tumor response up to 6 months. The final series consisted of 76 patients due to exclusion based on technical limitations in elastography acquisition, inability to undergo treatment, or loss to follow-up. Correlations between stiffness, pathological characteristics, and clinical outcomes were statistically assessed. Subgroup analyses were performed by treatment type but given the sample size, these results should be interpreted with caution and as exploratory.
RESULTS: Baseline tumor stiffness showed no correlation tumor type (p = 0.48) or lesion size (p = 0.35). Tumor stiffness increased after ablation (p = 0.02) and TACE (p = 0.04) but remained stable following TARE (p = 0.69). No significant changes were detected in peritumoral or liver stiffness after treatment. Despite these findings, no significant correlation was found between baseline tumor stiffness (p = 0.72), peritumoral stiffness (p = 0.61), liver stiffness (p = 0.29) and short-term clinical outcomes.
CONCLUSIONS: 2D-SWE showed measurable changes in tumor stiffness after locoregional treatments, suggesting a potential role in monitoring tissue alterations. However, no evidence was found to support its ability to predict treatment response or clinical outcomes. These findings should be interpreted as preliminary, and further validation in larger and homogeneous cohorts is needed.
引用
- Pisoni S, Pérez Enguix D, Picado Bermúdez A, et al. "Liver stiffness variations after locoregional treatment do not predict outcomes in liver cancer: limitations of elastography as a prognostic tool". Abdom Radiol (NY). 2026. PMID: 41801380. doi:10.1007/s00261-026-05394-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。